Kirby McInerney LLP reminds investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026. The lawsuit alleges that ADMA engaged in an undisclosed related party transaction, used channel stuffing to create an appearance of revenue, and lacked adequate internal controls. Following a March 24, 2026 short seller report by Culper Research alleging channel stuffing and an undisclosed related party distributor, ADMA shares fell 17% on March 24 and an additional 15% on March 25. A subsequent downgrade by Cantor Fitzgerald on March 26, citing lack of clarity and cash flow inconsistencies, led to a further 14% decline. Investors have until August 10, 2026 to request lead plaintiff appointment.
ADMA Biologics IncSecurities fraud lawsuit alleging undisclosed related party transaction, channel stuffing, and inadequate internal controls.